| Serial Number | 79365404 |
| Word Mark | DEVELOPICK |
| Filing Date | Tuesday, January 31, 2023 |
| Status | 616 - REVIVED - AWAITING FURTHER ACTION |
| Status Date | Tuesday, May 14, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Custom manufacture of polyclonal antibodies for pharmaceutical use; custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; processing of plant hormones being phytohormones; processing of medicinal materials; processing of pharmaceutical preparations; custom manufacture of pharmaceuticals; processing of pharmaceuticals; custom manufacture of pharmaceutical bispecific antibodies; processing of chemical reagents |
| Pseudo Mark | DEVELOP PICK |
| Goods and Services | Advisory services relating to technological research in the field of pharmaceutical manufacturing processes; advisory services relating to scientific analysis in the field of nucleic acids; research relating to science, namely, scientific research; conducting of technical feasibility studies, namely, conducting of feasibility studies in the field of new technologies; multiple nucleic acid scientific analysis; multiple nucleic check, namely, materials testing; analysis of materials; materials testing and evaluation; chemical analysis services for use in the testing of material; molecular analysis, namely, scientific analysis in the field of molecular biology; advisory services relating to biotechnology; technical management advisory services relating to biotechnology, namely, scientific research consulting, biotechnology consultancy services; biochemical analysis; advisory services relating to biochemistry research; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; design of new products for others; technical advice relating to safety, namely, consumer product safety testing consultation; pharmaceutical research and development; pharmaceutical products evaluation; clinical research in the field of medicines; services for assessing the efficiency of pharmaceuticals, namely, testing of pharmaceuticals; testing of raw materials; fusion protein analysis being testing of raw materials; computer programming services in the medical field; computer project management services relating to imaging medical data; medicine research being medical research; scientific analysis and quality evaluation of medical product development; pharmaceutical technology advisory service, namely, computer technology consultancy; pharmaceutical product evaluation; providing scientific and medical information on the testing, inspection and research of medical products; pharmaceutical product evaluation; scientific laboratory services relating to the production of bispecific antibody; bispecific antibody drug development; double antibody reagent scientific research and development; evaluating of clinical trial progress, namely, conducting clinical trials for others; clinical research, namely, conducting clinical trials for others; evaluation of product development being product quality evaluation; product safety testing; quality assurance consultancy in the field of pharmaceuticals; quality assessment being product testing; scientific research advisory services relating to chemical reagents; evaluation of chemical syntheses being product quality evaluation |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, March 17, 2023 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, March 17, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Samsung Biologics Co., Ltd. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Event Date | Event Description |
| Thursday, March 16, 2023 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, March 17, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, March 21, 2023 | APPLICATION FILING RECEIPT MAILED |
| Monday, October 30, 2023 | ASSIGNED TO EXAMINER |
| Wednesday, November 1, 2023 | NON-FINAL ACTION WRITTEN |
| Thursday, November 2, 2023 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, November 2, 2023 | REFUSAL PROCESSED BY MPU |
| Thursday, November 2, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Wednesday, November 22, 2023 | REFUSAL PROCESSED BY IB |
| Tuesday, May 14, 2024 | TEAS PETITION TO REVIVE RECEIVED |
| Tuesday, May 14, 2024 | PETITION TO REVIVE-GRANTED |
| Tuesday, May 14, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, May 14, 2024 | NOTICE OF REVIVAL - E-MAILED |
| Friday, June 14, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, June 14, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, June 14, 2024 | ASSIGNED TO LIE |